MultiCell therapy prevents cancer recurrence

Specifically, the research examined the co-administration of MCT-465, a toll-like receptor (TLR) agonist and IgNP, the company's antigen presenting immunoglobulin therapeutic. It found that the combination therapy not only destroyed cancerous tumors but conferred protection against new tumor growth, or recurrence of the disease.

Scientists demonstrated that mice previously treated with the IgNP/MCT-465 combination therapy which demonstrated tumor remission, remained immune to the development of new cancers. The challenged mice were completely protected against secondary cancers, whereas the control group of mice developed tumors with a 100% rate.

“Previously we demonstrated conclusively that co-administration of MCT-465 with our patented antigen-presenting immunoglobulin therapeutic ('IgNP') completely destroyed tumors and prevented mortality,” said Dr. Stephen Chang, chief executive officer of MultiCell Technologies.

“Now we have demonstrated that this same therapy prevents the recurrence of secondary cancers in animal models. Additionally, the T-cells from the immunized mice displayed a long-lasting, increased production of certain cytokines which are key players in the destruction of tumors.”